LRFN4 and breast carcinoma: Using the Kaplan-Meier plotter tool, high LRFN4 expression was associated with poor OS (P = 0.017), distant metastasis-free survival (DMFS, P = 0.019), and recurrence-free survival (RFS, P = 0.049) in breast cancer, and with progression-free interval (PFI) in various other cancer types.